David Bautz

James Molloy

Brian Kemp Dolliver

Emily Bodnar

Kemp Dolliver

Laura Suriel

Will Hidell

- **IMUNON, Inc. (Nasdaq: IMNN)** has **regained compliance** with the Nasdaq minimum bid price requirement for continued listing on The Nasdaq Capital Market.  **[749647_0001493152-25-012417_ex99-1.htm:0]** **[749647_0001493152-25-012417_form8-k.htm:1]** 
- The company received written notification from the Nasdaq Hearings Panel on **August 27, 2025**, confirming compliance with the $1.00 minimum closing bid price requirement.  **[749647_0001493152-25-012417_form8-k.htm:1]** 
- As a result, IMUNON common stock will continue **uninterrupted trading** on The Nasdaq Capital Market.  **[749647_0001493152-25-012417_ex99-1.htm:0]** 
- This compliance follows a recent **15% stock dividend** to shareholders of record as of August 7, 2025.  **[749647_0001493152-25-012417_ex99-1.htm:0]** 
- The company also noted the successful initiation of its **Phase 3 OVATION 3 trial** in North America for its lead clinical program, IMNN-001.  **[749647_0001493152-25-012417_ex99-1.htm:0]**

Imunon (IMNN)